Drug Type Natural Killer Cell Therapies |
Synonyms- |
Target- |
Action- |
Mechanism Immunologic cytotoxicity |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Erythroblastic Leukemia | Phase 2 | United States | 11 Jun 2013 | |
Acute Megakaryoblastic Leukemia | Phase 2 | United States | 11 Jun 2013 | |
Aggressive-Phase Chronic Myelocytic Leukemia | Phase 2 | United States | 11 Jun 2013 | |
Blast Phase Chronic Granulocytic Leukemia | Phase 2 | United States | 11 Jun 2013 | |
Chronic Myelomonocytic Leukemia | Phase 2 | United States | 11 Jun 2013 | |
High Risk Myelodysplastic Syndrome | Phase 2 | United States | 11 Jun 2013 | |
Myeloid Tumor | Phase 2 | United States | 11 Jun 2013 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 2 | United States | 11 Jun 2013 | |
Relapsing acute myeloid leukemia | Phase 2 | United States | 11 Jun 2013 | |
Treatment related acute myeloid leukaemia | Phase 2 | United States | 11 Jun 2013 |